|
REPLY TO THREAD
|
|
Subject
|
Another Vax success!!! Is worth the risk!
|
|
User Name
|
|
|
|
|
|
|
| Font color:
Font:
|
|
|
|
|
|
Original Message
|
BRITTNEY TELLS HER STORY - WHAT IS THE WORST THAT CAN HAPPEN?
[link to www.bitchute.com (secure)]
COVID VAXX INJURIES - YOUTUBER 'HEAL MY TECH' SUFFERS A STROKE (PART 1&2)
This NOT very rare condition!
That they have now put a warning for! Not for any in the USA!
Nope nothing from the cdc fda it's a secret!
The European Medicines Agency (EMA) is a decentralised agency of the European Union (EU) responsible for the scientific evaluation, supervision and safety monitoring of medicines in the EU.
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 27-30 September 2021
[link to www.ema.europa.eu (secure)]
COVID-19 Vaccine Janssen: risk of immune thrombocytopenia and venous thromboembolism
This DHPC informs healthcare professionals about immune thrombocytopenia (ITP) and venous thromboembolism (VTE).
For ITP, the DHPC highlights that cases of ITP have been reported within the first four weeks after receiving COVID-19 Vaccine Janssen, and that it included serious cases with very low platelet counts.
If an individual has a history of ITP, healthcare professionals should consider the risk of developing low platelet levels prior to administering the vaccine. In individuals with a history of ITP, it is recommended to monitor platelet levels following vaccination with COVID-19 Vaccine Janssen.
For VTE, it is described that VTE has been observed rarely following vaccination with COVID-19 Vaccine Janssen and that the risk of VTE should be considered for individuals with increased risk factors for thromboembolism (blood clots).
Individuals diagnosed with thrombocytopenia within three weeks after vaccination with COVID-19 Vaccine Janssen should be actively investigated for signs of thrombosis. Similarly, individuals who present with thrombosis within three weeks of vaccination should be evaluated for thrombocytopenia. This is important, to assess a potential diagnosis of thrombosis with thrombocytopenia syndrome (TTS), which requires specialised clinical management.
Vaxzevria: risk of thrombocytopenia including immune thrombocytopenia
This DHPC informs healthcare professionals of cases of thrombocytopenia (low levels of blood platelets) including immune thrombocytopenia (ITP) that have been reported with Vaxzevria, typically within the first four weeks after vaccination.
Very rarely, these events of thrombocytopenia presented with very low platelet levels and/or were associated with bleeding.
If an individual has a history of a thrombocytopenic disorder, healthcare professionals are advised to consider the risk of developing low platelet levels such as ITP, before administering the vaccine. Additionally, platelet monitoring is recommended after vaccination in an individual who has a history of ITP.
|
|
Pictures (click to insert)
|
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | | | Next Page >> |
|
